MLTX

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics (MLTX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.8
EV / EBITDA -2.6
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -21.9%
Price Return 12M 9.5%
Catalyst Signal 0.00
Market Cap $1.1B
TTM Revenue N/A
Price / Sales N/A
ROE -81.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C+ (2.5) C- (1.9) C- (2.0) D+ (1.8) C+ (2.6) C (2.2)
2026-11-06 C+ (2.5) D+ (1.8) C- (2.1) D+ (1.6) C+ (2.7) C- (2.1)
2026-10-30 C+ (2.5) D+ (1.8) C- (2.1) D+ (1.8) C+ (2.7) C (2.2)
2026-10-23 C+ (2.5) D+ (1.8) C- (2.1) C- (1.9) C+ (2.6) C (2.2)
2026-10-16 C+ (2.5) D+ (1.8) C- (2.1) D+ (1.6) C+ (2.6) C- (2.1)
Page 1 of 4